

# SENTARA COMMUNITY PLAN (MEDICAID)

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-800-750-9692. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. If the information provided is not complete, correct, or legible, the authorization process can be delayed.

### Preferred Cytokine and CAM antagonists (Pharmacy)

**Drug Requested:** (select the drug below that applies)

PREFERRED		
<input type="checkbox"/> <b>Humira</b> <sup>®</sup> (adalimumab)	<input type="checkbox"/> <b>Enbrel</b> <sup>®</sup> (etanercept)	<input type="checkbox"/> <b>Infliximab</b> <sup>*</sup> *(Refer to infliximab products PA form)

**MEMBER & PRESCRIBER INFORMATION:** Authorization may be delayed if incomplete.

Member Name: \_\_\_\_\_

Member Sentara #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

NPI #: \_\_\_\_\_

**DRUG INFORMATION:** Authorization may be delayed if incomplete.

Drug Name/Form/Strength: \_\_\_\_\_

Dosing Schedule: \_\_\_\_\_ Length of Therapy: \_\_\_\_\_

Diagnosis: \_\_\_\_\_ ICD Code, if applicable: \_\_\_\_\_

Weight (if applicable): \_\_\_\_\_ Date weight obtained: \_\_\_\_\_

DIAGNOSIS	Recommended Dose
<input type="checkbox"/> Ankylosing Spondylitis (AS)	<ul style="list-style-type: none"><li>• <b>Enbrel:</b> Four 50mg syringes, OR eight 25mg syringes per 28 days</li><li>• <b>Humira:</b> Two syringes/pens per 28 days</li></ul>
<input type="checkbox"/> Crohn's Disease (CD)	<ul style="list-style-type: none"><li>• <b>Humira:</b> 160 mg day 1, followed by 80 mg day 15 (6 syringes/28 days) for induction period, thereafter 40 mg every other week starting day 29 (2 syringes/28 days)</li></ul>

(Continued on next page)

DIAGNOSIS	Recommended Dose
<p>❑ <b>Hidradenitis Suppurativa (HS)</b></p>	<ul style="list-style-type: none"> <li>• <b>Humira:</b> 160 mg day 1, followed by 80 mg day 15 (6 syringes/28 days) for induction period, thereafter 40 mg once a week starting day 29 (4 syringes/28 days)</li> <li>• <b>Humira:</b> &gt;60 kg or more: 160 mg day 1, followed by 80 mg day 15(6 syringes/28 days) for induction period, thereafter 40 mg once a week starting day 29 (4 syringes/28 days)</li> <li>• <b>Humira:</b> 30-59 kg: 80 mg on day 1, then maintenance treatment of 40 mg once every other week starting on Day 29</li> </ul>
<p>❑ <b>Juvenile Idiopathic Arthritis (JIA)</b></p>	<ul style="list-style-type: none"> <li>• <b>Enbrel:</b> Four 50mg syringes, OR eight 25mg syringes per 28 days</li> <li>• <b>Humira:</b> Two syringes/pens per 28 days</li> </ul>
<p>❑ <b>Pediatric Crohn's Disease (CD)</b></p>	<ul style="list-style-type: none"> <li>• <b>Humira:</b> <ul style="list-style-type: none"> <li>• 37 lbs. to &lt; 88lbs: <ul style="list-style-type: none"> <li>• Initial month <ul style="list-style-type: none"> <li>• One syringes/pen 80mg</li> <li>• One syringes/pen 40mg</li> <li>• One syringes/pen 20mg</li> </ul> </li> <li>• Maintenance <ul style="list-style-type: none"> <li>• Two syringes/pens 20mg per 28 days.</li> </ul> </li> </ul> </li> <li>• ≥ 88 lbs: <ul style="list-style-type: none"> <li>• Initial month <ul style="list-style-type: none"> <li>• One syringes/pen 160mg</li> <li>• One syringes/pen 80mg</li> <li>• One syringes/pen 40mg</li> </ul> </li> <li>• Maintenance <ul style="list-style-type: none"> <li>• Two syringes/pens 40mg per 28 days</li> </ul> </li> </ul> </li> </ul> </li> </ul>
<p>❑ <b>Plaque Psoriasis (PsO)</b></p>	<ul style="list-style-type: none"> <li>• <b>Enbrel:</b> Eight, 50mg syringes per 28 days for the initial 3 months</li> <li>• <b>Enbrel:</b> Four, 50mg syringes per 28 days after induction period</li> <li>• <b>Humira:</b> Four syringes/pens in the initial 28 days</li> <li>• <b>Humira:</b> Two syringes/pens per 28 days after induction period</li> </ul>
<p>❑ <b>Polyarticular Juvenile Idiopathic Arthritis (pJIA)</b></p>	<ul style="list-style-type: none"> <li>• <b>Enbrel:</b> Four, 50mg syringes, OR eight 25mg syringes per 28 days</li> </ul>
<p>❑ <b>Psoriatic Arthritis (PsA)</b></p>	<ul style="list-style-type: none"> <li>• <b>Enbrel:</b> Four 50mg syringes, per 28 days</li> <li>• <b>Humira:</b> Two syringes/pens per 28 days</li> </ul>

DIAGNOSIS	Recommended Dose
<input type="checkbox"/> Psoriatic Arthritis (PsA)	<ul style="list-style-type: none"> <li>• <b>Enbrel:</b> Four 50mg syringes, per 28 days</li> <li>• <b>Humira:</b> Two syringes/pens per 28 days</li> </ul>
<input type="checkbox"/> Rheumatoid Arthritis (RA)	<ul style="list-style-type: none"> <li>• <b>Enbrel:</b> Four 50mg syringes, OR eight 25mg syringes per 28 days</li> <li>• <b>Humira:</b> Two syringes/pens per 28 days</li> </ul>
<input type="checkbox"/> Ulcerative Colitis (UC)	<ul style="list-style-type: none"> <li>• <b>Humira:</b> Six syringes/pens in the initial 28 days</li> <li>• <b>Humira:</b> Two syringes/pens per 28 days after induction period</li> </ul>
<input type="checkbox"/> Uveitis (UV)	<ul style="list-style-type: none"> <li>• <b>Humira:</b> Adults: (Four syringes in the initial 28 days), then Two syringes/ pens per 28 days after induction period.</li> <li>• <b>Humira:</b> Children 2-17 years old: <ul style="list-style-type: none"> <li>• 30kg or more: 40mg every other week</li> <li>• 15-29kg: 20mg every other week</li> <li>• 10-14kg: 10mg every other week</li> </ul> </li> </ul>

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

<input type="checkbox"/> Ankylosing Spondylitis (AS) Dosing: _____	<input type="checkbox"/> Crohn's Disease (CD) Dosing: _____
<input type="checkbox"/> Hidradenitis Suppurativa (HS) Dosing: _____	<input type="checkbox"/> Juvenile Idiopathic Arthritis (JIA) Dosing: _____
<input type="checkbox"/> Plaque Psoriasis (Ps) Dosing: _____	<input type="checkbox"/> Psoriatic Arthritis (PsA) Dosing: _____
<input type="checkbox"/> Rheumatoid Arthritis (RA) Dosing: _____	<input type="checkbox"/> Ulcerative Colitis (UC) Dosing: _____
<input type="checkbox"/> Uveitis (UV) Dosing: _____	<input type="checkbox"/> Polyarticular Juvenile Idiopathic Dosing: _____
<input type="checkbox"/> Other: _____ Dosing: _____	

**Medication being provided by Specialty Pharmacy - PropriumRx**

***\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\****  
***\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\****